FIM
NTLA icon

Freedom Investment Management’s Intellia Therapeutics NTLA Stock Holding History

Freedom Investment Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,345
Closed -$243K – 763
2022
Q3 		$243K Buy
4,345
+210
+5% +$13K 0.03% 612
2022
Q2 		$214K Buy
+4,135
New +$210K 0.02% 669
2022
Q1 		– Sell
-3,058
Closed -$362K – 892
2021
Q4 		$362K Buy
3,058
+57
+2% +$7.14K 0.03% 619
2021
Q3 		$403K Sell
3,001
-1,852
-38% -$280K 0.03% 569
2021
Q2 		$786K Sell
4,853
-2,308
-32% -$180K 0.06% 401
2021
Q1 		$575K Buy
+7,161
New +$481K 0.04% 473

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Freedom Investment Management's NTLA Position: Q4 2022 in Review

Freedom Investment Management sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 4,345 shares — an estimated $243K sold.

Freedom Investment Management first reported a position in NTLA in Q1 2021 and held it in 6 quarters. The position peaked at $786K in Q2 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

  • Freedom Investment Management reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Freedom Investment Management sold 4,345 Intellia Therapeutics shares in Q4 2022, an estimated $243K.
  • Freedom Investment Management first reported a position in Intellia Therapeutics in Q1 2021 and held it in 6 quarters.
  • Freedom Investment Management's Intellia Therapeutics position peaked at $786K in Q2 2021.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on Freedom Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.